

FORM 7

MONTHLY PROGRESS REPORT

For March 2018

Name of Listed Issuer: **Liberty Health Sciences Inc. (formerly, SecureCom Mobile Inc.)** (the "Issuer" or "Company").

Trading Symbol: **LHS**

Number of Outstanding Listed Securities: **303,358,348 common shares**

Date: **April 3, 2018**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On March 27th, the Company announced the acquisition of a 75% ownership interest in William Noyes Webster Foundation Inc. (WNWF), the owner of an integrated medical marijuana license in the state of Massachusetts. WNWF has a cultivation facility and a dispensary location both nearing completion, as well as leases and local governmental approvals in place for two additional dispensary locations. Pending application approval by the Massachusetts Department of Public Health, the Transaction will also provide Liberty with two additional integrated medical cannabis licenses. Medical cannabis license holders such as WNWF in Massachusetts will be given priority over non-license holders to acquire state recreational cannabis licenses on April 1, 2018 via conversion applications that WNWF will file with the newly formed Cannabis Control Commission. License holders will be eligible to receive three recreational licenses for each medical license for cultivating, processing and dispensing cannabis. The transaction to acquire the 75% ownership interest is expected to close in May 2018.

The Company intends to continue to look at strategic avenues for growth including, but not limited to, evaluating targets for expansion in key U.S. states that have approved medical use of marijuana and meet its stringent investment criteria.

2. Provide a general overview and discussion of the activities of management.

In addition to overseeing the retrofit activities at Liberty 360 (Alico), Management continues to seek potential dispensary sites and is in the process of negotiating additional leases.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

On March 21st, the Florida Department of Health, Office of Medical Marijuana Use, approved the production and sale of THC concentrate product by the Company. The product should be available for patients before the end of April.

On March 23rd, the Florida Department of Health, Office of Medical Marijuana Use, approved the production and sale of Mary's Medicinals line of trans-dermal products by the Company. The trans-dermal products should be available for patients by May.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report in the month of March.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report in the month of March.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report in the month of March.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Refer to #1 above and the deal to acquire a 75% ownership interest in the William Noyes Webster Foundation Inc., an integrated medical license holder in Massachusetts. No other transactions to report for the month of March.

8. Describe the acquisition of new customers or loss of customers.

The Company continues to grow its number of patients as the overall Florida market increases in terms of registered patients.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None to report in the month of March.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

On March 21, 2018 the Company announced that t Jennifer Timothee Oliveras, M.D. would be joining the Company as Medical Director, overseeing Liberty's patient-focused approach to selling medical cannabis.

The Company continues to add personnel in the areas of patient care and product deliveries in the Florida operations as well as dispensaries with the expected opening of additional dispensaries over the next 60-90 days.

There were no significant terminations or lay-offs in the month of March.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report in the month of March.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report in the month of March.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

No new debt to report for the month of March.

14. Provide details of any securities issued and options or warrants granted.

No new securities, options or warrants were issued in the month of March.

15. Provide details of any loans to or by Related Persons.

None to report in the month of March.

16. Provide details of any changes in directors, officers or committee members.

None to report in the month of March.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

On March 23rd, US Congress passed the 2018 omnibus appropriations package, which includes the Rohrabacher-Leahy Amendment ("Rohrabacher-Leahy")

restricting the Department of Justice (“DOJ”) from interfering with the rights of patients and medical cannabis companies such as Liberty operating in compliance with State laws. As a result, the DOJ will not be able to pursue enforcement actions against legal medical cannabis cultivators, distributors and licensees operating in compliance with State laws, thereby protecting Liberty’s business, operations and patients.

The support for Rohrabacher-Leahy from Congress and the White House marks a significant reversal in Federal policy since the January 4, 2018, memorandum issued by Attorney General Jeff Sessions. That memo rescinded the Obama-era Cole Memorandum that afforded state-licensed cannabis businesses protection from prosecution. With those protections effectively restored, Liberty will continue to pursue its aggressive growth strategy, which focuses on those states where a robust legal regime exists for medical cannabis.

There were no other significant change in trends and risks in the month of March which are likely to impact the Company during the period.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. To the best of the undersigned's knowledge and belief, as of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that, to the best of the undersigned's knowledge and belief, the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. To the best of the undersigned's knowledge and belief, all of the information in this Form 7 Monthly Progress Report is true.

Dated April 3, 2018.

Rene Gulliver
Name of Director or Senior Officer

"Rene Gulliver"
Signature

CFO
Official Capacity

Issuer Details Name of Issuer Liberty Health Sciences Inc. (formerly, SecureCom Mobile Inc.)	For Month End March 28, 2018	Date of Report YY/MM/DD 18/04/03
Issuer Address 35 McCaul Street, 2nd Floor		
City/Province/Postal Code Toronto, ON M5T 1V7	Issuer Fax No.	Issuer Telephone No.
Contact Name Rene Gulliver	Contact Position CFO	Contact Telephone 416-884-0791
Contact Email Address rgulliver@libertyhealthsciences.com	Web Site Address https://libertyhealthsciences.com/	